BBOT announces new BBO-8520 data and combo strategy
BBOT says it has new BBO-8520 data, highlighting a focus on its BBO-8520 combination for 2L+ NSCLC and combo programs in KRAS-mutant cancers.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.